Business Wire

Thales High Tech to Offer Thai Citizens One of the World’s Most Secure E-Passports

Share

Even though the COVID-19 health crisis has been severely disrupting the global travel industry, in the past few months the DGM Consortium has continued its close collaboration with MOFA. Global teams were working remotely to deliver the project, supporting the Thai Government’s ‘Thailand 4.0’ vision to develop an innovative, digital economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005034/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Thai passports (Photo: Thales)

The new Thai e-passport project was delivered on the 8th of July to MOFA and launched in an official inauguration ceremony conducted on the 5th of August in the presence of Minister Don Pramudwinai, Minister of Foreign Affairs of Thailand.

The Thai e-passport project is one of the largest passport programs for Thales worldwide, as it aims to provide Thai citizens superior technology and the highest possible level of security in a travel document.

The newly designed 64-page biometric travel document includes an e-Cover and a thin, flexible data page made of polycarbonate material. The reverse side of the data page features a high definition, true color UV picture of one of Bangkok’s most iconic landmarks, the Wat Arun temple. The security features visible on the data page include an additional secondary image of the citizen perforated in the semi-transparent window; as well as the traditional Thai four-petal lotus symbol, the line-pra-jum-yam, embossed using Thales’ Secure Surface technology.

Designed to counter new types of forgeries, Thales Secure Surface provides optical elements with light reflective and animation effects revealed by tilting a document in different angles. This visible security feature allows fast and efficient verification by border authorities.

An additional perceptible feature is the tactile signature of the citizen embossed on the data page. Biometric data is securely embedded into the passport chip using Thales’ secure embedded software. This software provides strong security for identification and protection of citizens’ privacy.

The technological features of the passport ensures secure and fast border crossing, while complying with all relevant data protection laws in Thailand and is fully compliant to the highest security standards recommended by the International Civil Aviation Organisation (ICAO).

Since the project’s inception, Thales has trained 250 local experts in its passport issuance technologies. Over the next seven years, Thales will be operating know-how transfer and upskilling more than 500 Thai nationals in its technologies, thus significantly contributing to the local economy.

Thales has been a dedicated partner to Thailand for almost 50 years in industry sectors ranging from defence to air traffic management and ground transportation. Aligning with this vision Thales will henceforth be providing its digital identity and biometrics expertise to the Thai Ministry of Foreign Affairs, making the Group their trusted partner as they deliver a highly-secure and modern passport for their citizens.

“I am delighted that Thales has successfully delivered this new generation passport to Thai citizens and helped the Ministry of Foreign Affairs (MOFA) strengthen homeland protection and safeguard their citizens’ identities. Throughout the last few months amidst the global COVID-19 pandemic, we have continued our close collaboration with MOFA and worked tirelessly to deliver this milestone. Thai citizens now possess one of the world’s most sophisticated e-passports that integrate biometrics and other high-security features that will provide a seamless and secure travel experience. We will continue to build local expertise in passport issuance with training and transfer-of-technology aligned with our commitment to upskilling the Thai workforce as Thailand moves towards a digital future.”Massimo Marinzi, Country Director, Thales in Thailand

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thales, Media relations
Digital Identity & Security
Vanessa Viala
+33 (0) 6 89 73 25 47
vanessa.viala@thalesgroup.com

Thales, South East Asia Communications
Serene Koh
+65 6594 6898
serene.koh@asia.thalesgroup.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye